TEVA's Ecopipam Wins FDA Priority Tag in Pediatric Tourette Syndrome

Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

Zacks Investment Research • Aug 20, 2026

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Benzinga • Aug 20, 2026

U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advances Teva's Pivot to Growth strategy by utilizing the company's expertise in neuroscience to support patients, particularly in areas where there is high unmet need.

GlobeNewsWire • Aug 19, 2026

Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?

Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.

Zacks Investment Research • Aug 19, 2026

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Business Wire • Aug 19, 2026

Humana agrees not to reference Teva's Israel ties at US drug trial

Health insurer Humana has ‌agreed not to refer to drugmaker Teva as an Israeli company at an upcoming U.S. drug price-fixing trial, after the drugmaker said public views on the Gaza war could unfairly influence jurors.

Reuters • Aug 13, 2026

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Aug 7, 2026

Teva seeks to keep Israel ties from jury, cites Gaza war

Teva Pharmaceuticals has asked a U.S. judge to ​prevent insurer Humana from telling jurors it is an Israeli company at a major drug ‌price-fixing trial, arguing that strong public views over the Gaza war could prejudice proceedings and affect its ability to receive a fair hearing.

Reuters • Aug 6, 2026

Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan

Teva Pharmaceutical Industries Limited is executing a successful turnaround, driven by its "Pivot to Growth" strategy and strong innovative medicines performance. Management raised 2026 guidance for Austedo, Ajovy, and Uzedy, targeting $3.7B specialty revenue (17% y/y growth) and a robust pipeline through 2030. Generics and biosimilars remain stable, funding R&D for innovation, while margin improvements and debt reduction enhance the risk/reward profile.

Seeking Alpha • Aug 5, 2026

Teva's Re-Rating Still Has Room To Run

Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026.

Seeking Alpha • Aug 3, 2026